secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2026-08-26T20:05:57+00:00
Accession:  0001193125-26-368296
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase dismisses CohnReznick, appoints Deloitte as new auditor
------------------------------------------------------------------

- Dismissed CohnReznick effective Aug 21, 2026; no disagreements on accounting principles or practices.
- Appointed Deloitte & Touche as independent auditor for FY2026, effective immediately after dismissal.
- CohnReznick's audit reports for FY2024 and FY2025 were unqualified; no adverse or modified opinions.
- Material weakness in internal control over financial reporting disclosed in Q2 2024 was remediated by Q3 2024.
- CohnReznick letter to SEC dated Aug 26, 2026 filed as Exhibit 16.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526368296/0001193125-26-368296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526368296/d904831d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-368296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer